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Summary Although case-oriented evidence for an association of Epstein-Barr virus (EBV) with gastric
carcinoma has been accumulating recently, the interaction(s) between EBV and gastric epithelial cells is/are
largely unknown. In this study, we examined seven EBV-positive gastric carcinoma tissues for viral gene
expression at the mRNA level, from which studies on the EBV oncogenicity in human epithelial cells will
benefit. Reverse transcription-PCR analysis showed that all seven EBV-positive tumour tissues constitutively
expressed EBV nuclear antigen (EBNA) 1 mRNA, but not EBNA2 mRNA. The EBNA transcription was
initiated from one of three EBNA promoters, Qp; by contrast, both Cp and Wp were silent, thus resulting in
the lack of EBNA2 mRNA. Latent membrane protein (LMP) 2A mRNA was detected in three of seven cases;
however, neither LMP1 nor LMP2B mRNA was detected in any of the tumours tested. Transcripts from the
BamHI-A region of the viral genome were detectable in all cases. BZLF1 mRNA and the product, an
immediate-early gene for EBV replication, was not expressed in any of them, thereby suggesting that the
tumour cells carried EBV genomes in a tightly latent form. These findings further extended our previous data
regarding EBV latency in gastric carcinoma cells at the protein level, and have affirmed that the programme of
viral gene expression in the tumour more closely resembles 'latency IF represented by Burkitt's lymphoma than
'latency II' represented by the majority of nasopharyngeal carcinomas.
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Epstein -Barr virus (EBV) is a ubiquitous human herpes
virus, closely associated with the genesis of Burkitt's
lymphoma (BL), undifferentiated nasopharyngeal carcinoma
(NPC) and opportunistic lymphomas in immunocompro-
mised hosts (Liebowitz and Kieff, 1993). Recent studies
demonstrated that EBV is also implicated in Hodgkin's
disease (HD) (Herbst et al., 1991; Pallesen et al., 1991),
certain T-cell lymphomas (Harabuchi et al., 1990; Su et al.,
1991; Korbjuhn et al., 1993) and thymic carcinoma (Leyvraz
et al., 1985; Dimery et al., 1988; Patton et al., 1994). All or a
significant proportion of neoplastic cells of the tumours
harbour EBV DNA and express virus-coded latent infection
(immortalisation-associated) proteins. Some of these EBV-
related malignancies have been precisely analysed for viral
latent gene expression and show characteristic patterns for
each individual tumour (Liebowitz and Kieff, 1993).
Over ten major EBV genes are known to be potentially
transcribed in cells latently infected with the virus: EBV
nuclear antigens (EBNA) 1, -2, -3A, -3B, -3C and leader
protein (LP); latent membrane proteins (LMP) 1, -2A, and -
2B; untranslated EBV-encoded small RNAs (EBER)-1 and -2
(Liebowitz and Kieff, 1993); and a recently found transcript
containing the BamHI-A rightward open reading frame
(BARFO) (Gilligan et al., 1990). All the latent transcripts
are regularly expressed in in vitro EBV-immortalised B-
lymphoblastoid cell lines (LCL) and some B lymphoproli-
ferative disorders occurring in immunosuppressed patients
(latency III) (Young et al., 1989; Kerr et al., 1992). In
contrast, only EBERs, EBNA1 and BamHI-A transcripts are
expressed in most in vivo BL cells and several BL cell lines
(latency I), which are referred to as group I BL cells (Rowe et
al., 1987; Brooks et al., 1993); and three LMP genes are
additionally expressed along with EBERs, EBNA1 and
BamHI-A RNAs in the majority of NPC and HD (latency
II) cases (Kerr et al., 1992; Deacon et al., 1993).
Furthermore, the combination of EBNA mRNA expressed
depends on which of three mutually exclusive EBNA
promoters, BamHI-C, -W and -Q promoters (Cp, Wp and
Qp respectively), is active. The Cp- or Wp-initiated large
primary transcript is differentially spliced into all six EBNA
mRNAs as is seen in cells with latency III (e.g LCL) (Rogers
et al., 1990), whereas Qp mediates the selective expression of
only EBNA1 mRNA through bypassing coding regions of the
other EBNA genes, consequently leading to the complete lack
of EBNA2, -3A, -3B, -3C and -LP mRNAs represented by
group I BL and NPC cells (Schaefer et al., 1995a; Nonkwelo
et al., 1996).
Gastric carcinoma, the most common malignancy in
Japan, is being recognised as one of the EBV-related
tumours (Shibata et al., 1991; Imai et al., 1994). Although
our previous work revealed that about 7% of Japanese
gastric carcinomas were EBV genome-positive and that, in
addition to EBERs, EBNA1, but not the other EBNAs or
LMP1, protein was expressed in the tumour cells (Imai et al.,
1994), details about expression of the other latent genes,
LMP2A, -2B and BARFO, and about utilisation of an EBNA
promoter, which is also necessary to understand the EBV-
induced oncogenic process, are still unknown. In this study,
we analysed seven EBV-positive gastric carcinomas more
extensively for virus latent and replication cycle gene
expression together with EBNA promoter usage at the
mRNA level, using the reverse transcription -polymerase
chain reaction (RT-PCR) technique.
Materials and methods
Subjects
Tumour tissues used in this study were resected or
endoscopically biopsied from the stomachs of seven patients
with EBV-positive gastric carcinoma and six patients with
EBV-negative gastric carcinoma. The clinical and histological
data of the patients with EBV-positive gastric carcinoma are
shown in Table I. The six EBV-negative tumours consisted of
two well differentiated, two moderately differentiated and two
Correspondence: S Imai
Received 21 September 1995; revised 6 February 1996; accepted 13
March 1996EBV gone expression in gastric carcinoma
M Sugiura et al
626
poorly differentiated histological types. EBV positivity of the
cases was screened by the PCR assay for EBV DNA and in
situ hybridisation for EBERI as previously described (Imai et
al., 1994). All tumour specimens were snap frozen and stored
at -80°C until use. They were obtained after informed
consent of the patients and used according to the guidelines
of the Committee for Experimentation and Protection of
Human Subjects, Cancer Institute, Hokkaido University
School of Medicine.
Cell lines
All cell lines used were maintained in the exponential growth
phase in RPMI-1640 culture medium supplemented with 10%
heat-inactivated fetal calf serum. An EBV-transformed LCL
was used as a positive control for detection of EBNA1, -2,
LMP1, -2A, -2B mRNAs; Cp- and Wp-initiated EBNA
mRNAs; and BamHI-A transcripts. A group I BL cell line,
Akata (Takada and Ono, 1989), served as a positive control
for Qp-initiated EBNA mRNA. For detection of the EBV
replication-associated BZLF1 gene mRNA (Countryman et
al., 1987), B95-8 cells (Miller and Lipman, 1973) or Akata
cells, in which the virus replication cycle was induced by
cross-linking of the surface immunoglobulin (Ig)G by
treatment with goat antibodies to human IgG (Cappel
Research Products, Durham, NC, USA) (Takada and Ono,
1989), was used as a control. A B-lymphoma cell line, BJAB,
was used as an EBV-negative control (Klein et al., 1975).
RNA extraction and cDNA synthesis
RNA extraction was carried out within one month of the
storage period. After pulverisation of the frozen tissues in a
micro-homogeniser, total RNA was extracted by using Trizol
reagent (Gibco BRL, Gaithersburg, MD, USA) according to
the manufacturer's protocol, precipitated with isopropanol in
the pressence of 1 yg of glycogen (Boehringer, Mannheim,
Germany). The precipitate was pelleted by centrifugation at
15 000 r.p.m. for 15 min, washed twice with ice-cold 75%
ethanol, dried and dissolved in diethyl pyrocarbonate
(DEPC)-treated distilled water. After DNAase I (Gibco
BRL) treatment at 37°C for 15 min followed by 10 min
Table I EBV gene expression in EBV-positive gastric carcinomas
EBNAI Active EBNA promoter LMP BamHI-A
Case no Age Sex Histological type (U/K) EBNA2 Cp Wp QP I 2A 2B transcripts BZALI
1 81 F Undifferentiated (lym- + - - - + -- +
phoepithelioma-like)
2 55 M Poorly differentiated + - - - + - + - + -
3 67 M Poorly differentiated + - - - + - - +
4 71 M Moderately differentiated + - - - + - - +
5 72 M Moderately differentiated + - - - + - - + -
6 55 M Moderately differentiated + - - - + - + - +
7 53 M Well differentiated + - - - + - + - + -
Table II The sequences and coordinates of primers and probes used in this study
Transcript Product size Sequence (5'-3') B95-8 genomic coordinates
EBNA1 273 bp 5' primer GATGAGCGTTTGGGAGAGCTGATTCTGCA 67510-67539
3' primer TCCTCGTCCATGGTTATCAC 108075-108056
Probe AGACCTGGGAGCAGATTCAC 67608-67627
EBNA2 339 bp 5' primer GCTGCTACGCATTAGAGACC 47892-47911
3' primer TCCTGGTAGGGATTCGAGGG 48616-48597
Probe CAGCACTGGCGTGTGACGTGGTGTAAAGTT 48391 -48420
Qp initiated 339 bp 5' primer AGGCGCGGGATAGCGTGCGCTACCGGA 62426-62452
3' primer TCCTCGTCCATGGTTATCAC 108075-108056
Probe AGACCTGGGAGCAGATTCAC 67608-67627
Cp initiated 297 bp 5' primer CACTACAAGACCTACGCCTCTCCATCCATC 11425-11454
3' primer TCTCCCCTAGGCCCTGAAGGTGAACCGCTT 14832-14813, 17636-17626
Probe GCGACCGGTGCCTTCTTAGGAGCTGTCCGA 14708-14737
Wp initiated 235 bp 5'primer TCAGAGCGCCAGGAGTCCACACAAAT 14384-14410
3' primer TCTCCCCTAGGCCCTGAAGGTGAACCGCTT 14832-14813, 17636- 17626
Probe GCGACCGGTGCCTTCTTAGGAGCTGTCCGA 14708-14737
LMP1 490 bp 5' primer TCCTCCTCTTGGCGCTACTG 169383- 169364
3' primer TCATCACTGTGTCGTTGTCC 168740-168759
Probe GAACAGCACAATTCCAAGGAACAATGCCTG 169061-169090
LMP2Aa 280 bp 5' primer ATGACTCATCTCAACACATA 166874-166893
3' primer CATGTTAGGCAAATTGCAAA 380-361
Probe ATCCAGTATGCCTGCCTGTA 62-81
LMP2Ba 325 bp 5' primer CAGTGTAATCTGCACAAAGA 169819-169838
3' primer CATGTTAGGCAAATTGCAAA 380-361
Probe ATCCAGTATGCCTGCCTGTA 62-81
BamHI-Ab 232 bp 5' primer AGAGACCAGGCTGCTAAACA 157154-157174
3' primer AACCAGCTlTTCCTTTCCGAG 159194- 159175
Probe AAGACGTTGGAGGCACGCTG 157359- 157378
BZLF1 453 bp 5' primer CATGTTTCAACCGCTCCGACTGG 102963-102941
3' primer GCGCAGCCTGTCATTTTCAGATG 102303-102325
Probe GCACGACGCACACGGAAACCACAACAGCCA 102661-102690
aBrooks et al., 1992; bBrooks et al., 1993.EBV gene expression in gastric carcinoma
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heating at 95°C, RNA was ethanol-precipitated again, then
resuspended in DEPC-treated water and dispensed into small
aliquots. To test the sensitivity of our RT-PCR system,
RNA was prepared from 106 appropriate control cells,
serially 10-fold diluted from a quantity equivalent to 105 to
100 cells, and the total RNA amount of each diluted sample
was adjusted to that of 105 cells by addition of RNA
extracted from BJAB cells. For cDNA synthesis, 10 pmol of
a 3'-primer specific for each transcript (Table II) was added
to the RNA sample, followed by heating at 94°C for 5 min
and rapid chilling on ice. Reagents were added to the RNA-
primer mixture to give a final concentration of 50 mM Tris-
HCI (pH 8.3), 75 mM potassium chloride, 3 mM magnesium
chloride, 10 mM dithiothreitol, 0.5 mm for each dNTP, 10 U
of RNasin (Promega, Madison, WI, USA) and 200 U of
Molony murine leukaemia virus reverse transcriptase (Gibco
BRL). Reverse transcription was performed at 37°C for
60 min in a total volume of20 pl and then heated at 940C for
3 min to stop the reaction.
PCR and detection ofamplified products
Full details of the sequences and genome coordinates of
primers and probes used to detect EBV transcripts are given
in Table II. Our original primer pairs were designed in
different exons for individual EBV transcripts so that
occasional amplification of contaminated genomic DNA, if
any, could be easily discriminated from the relevant RNA
amplification by product size. The PCR reaction mixture
consisted of 20 mM Tris-HCl (pH 8.4), 50 mM potassium
chloride, 1.5 mm magnesium chloride, 0.01% gelatin, 200 pM
of each dNTP, 20 pmol of each primer and synthesised
EBNA1 CpC 4
Wp Wi W2 -U K
M WO 1 QP27
M P 1 2 3 4 5 6 7 8 9 10
273 bpm
cDNA, in a total volume of 100 pl. After it was overlaid with
mineral oil, the reaction mixture was heated to 94°C for
3 min, slowly cooled to 70°C, and then 2.5 U of Taq
polymerase (Gibco BRL) was added to the tubes. Samples
were then subjected to 35 cycles of amplification by a
Thermal Cycler 480 (Perkin-Elmer, Foster City, CA, USA),
each cycle consisting of 94°C for 1 min (denaturation), 45°C
for 2 min (annealing) and 72°C for 3 min (DNA extension).
The extension time was prolonged to 6 min in the last cycle.
The quality of RNA preparations was simultaneously
checked by 30 cycles of amplification of cytoplasmic fl-actin
mRNA with the antisense primer (5'-GGAGCAAT-
GATCTTGATCTTC-3') and the sense primer (5'-
CCTTCCTGGGCATGGAGTCCT-3') (Busson et al., 1992).
The PCR products were electrophoresed in 1.5% agarose gels
(SeaKem; Takara, Otsu, Japan), stained with ethidium
bromide (Et-Br), and photographed under a UV-transillumi-
nator. They were denatured in an alkali solution for 20 min
with gentle rocking and directly blotted onto nylon
membranes (Biodyne-B; Pall, Glen Cove, NY, USA) by
vacuum transfer. The blotted membranes were fixed with a
UV-crosslinker (Bio Rad, Richmond, CA, USA) and then
subjected to hybridisation with [y-32P]ATP-5'-end-labelled
internal oligonucleotide probes. The exposure time of
autoradiograph was 6-12 h for viral transcripts and 2 h
for ,B-actin mRNA.
Immunofluorescence assay
Frozen tissue sections of EBV-positive gastric carcinomas
were examined for expression of the BZLF1 protein by
streptavidin-biotin immunofluorescence, using mouse BZ.1
LMP1
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Figure 1 Detection ofEBNA1, EBNA2 and LMPl mRNAs by RT-PCR in EBV-positive and -negative gastric carcinoma tissues.
Results are shown by ethidium bromide (Et-Br) staining (upper) and Southern hybridisation with 32P-labelled probes (lower). Lane
M, (DX174-HaeIII digest as a size marker; lane P, PCR product of RNA extracted from LCL as an EBV-positive control; lanes 1-
7, PCR products of RNAs from EBV-positive gastric carcinoma tissues of case nos. 1-7 (Table I) respectively; lanes 8-10, PCR
products of RNAs extracted from three EBV-negative gastric carcinoma tissues (well-differentiated, moderately differentiated and
poorly differentiated types respectively). The splice structures of each transcript analysed are shown by diagrams on the top of Et-
Br-stained gels. Open boxes and small arrows represent exons and the sites ofrelevant transcriptional EBNA promoters respectively.
The primer-probe combinations used are indicated as large arrows and bars. Simultaneous amplification of cytoplasmic ,B-actin
mRNA was carried out to check for pertinent RNA extraction. The predicted sizes of each viral transcript are indicated at the left
(bp).
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monoclonal antibody (Young et al., 1991; purchased from
Dakopatts). In this assay, B95-8 cells or surface IgG-cross-
linked Akata cells served as a BZLFl-positive control, and
non-treated Akata cells and EBV-negative gastric carcinoma
tissues served as the negative controls.
Results
Sensitivity of RT-PCR
In preliminary experiments using diluted RNA samples from a
reference LCL, the RT-PCR-Southern hybridisation system
with our original primer-probe combinations could detect
EBNA1 (with U/K exons), EBNA2, LMP1, BARFO and Cp-
initiated EBNA transcripts as well as LMP2A and -2B mRNAs
amplified with the primers previously reported (Brooks et al.,
1992), even at the single-cell level (data not shown). Wp- and
Qp-initiated EBNA and BZLF1 mRNAs were detectable at
RNA amounts equivalent to 10 LCL, untreated and sIg-
crosslinked Akata cells respectively (data not shown). Thus,
our RT-PCR systems were considered to have sensitivities
similar to or higher than those described in other RNA studies
on NPC and HD (Brooks et al., 1992; Deacon et al., 1993).
RT-PCR analysis of EBV latent gene expression in EBV-
positive gastric carcinomas
RT-PCR analyses revealed that EBNA1 mRNA with
BamHI-U and -K exons, which are commonly contained
in every EBNA1 transcript generated from any of the three
EBNA promoters, could be clearly detected in all seven
EBV-positive gastric carcinoma tissues (Figure 1). By
contrast, none of the tumour tissues expressed either
detectable EBNA2 or LMP1 mRNA, whereas the RNA
preparation from control LCL yielded strong signals and 1l-
actin mRNA was readily amplified from all tumour tissues
tested (Figure 1). The results were consistent with our
previous observations at the protein level (Imai et al., 1994).
We further investigated expression of LMP2A, -2B and
BamHI-A transcripts in EBV-positive gastric carcinoma,
which remain unknown so far. As shown in Figure 2,
LMP2A mRNA was detected in three of the seven cases,
although LMP2B mRNA was undetectable in all cases.
Transcripts from the BamHI-A fragment of the virus
genomes were also detected in all seven cases studied
(Figure 2). Based on the above results, the EBV latent
gene expression pattern in gastric carcinoma is delineated in
Table III, in comparison with the other representative EBV-
positive cell types. No mRNA investigated except for f-actin
was detected in six EBV-negative gastric carcinoma tissues
throughout the present study (Figure 1 and see below).
Promoter utilisation for EBNA transcription in EBV-positive
gastric carcinomas
Since the unequivocal detection of U/K-spliced EBNA1
mRNA with the concomitant absence of EBNA2 mRNA
suggested Qp-driven EBNA transcription, we next investi-
gated which of the three EBNA promoters actually mediated
EBNA gene expression in EBV-positive gastric carcinomas.
As expected, EBNA mRNA with the Q/U/K-spliced structure
was clearly detected in all cases tested, whereas mRNA with
C1/W2 or WO/W2 exons, diagnostic of Cp and Wp usage,
respectively, was not detected at all (Figure 3). It is unlikely
that the Q/U/K exon-containing EBNA1 transcript detected
here was initiated from the BamHI-F promoter (Fp), which
was initially reported to be a third EBNA promoter (Schaefer
et al., 1991; Sample et al., 1991) and redefined thereafter as
an early lytic promoter (Lear et al., 1992; Schaefer et al.,
LMP2A _
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Figure 2 Detection of LMP2A, LMP2B and BamHI-A
transcripts by RT-PCR in EBV-positive gastric carcinomas.
Results are shown by Et-Br staining (upper) and Southern
hybridisation with 32P-labelled probes (lower). The splice
structures of each transcript are shown by diagrams on the top
of Et-Br-stained gels. Diagrammatic items and lanes represent the
same ones as in the legend of Figure 1. The predicted sizes of viral
transcripts are indicated at the left (bp).
Table III EBV latent gene expression in various cell types
Type of EBNA Active EBNA promoter LMP BamHI-A
Cell type EBVlatency I 2,3s,LP Cp or Wp Qp 1 2A 2B transcript
Burkitt's lymphoma I + - - + +
Nasopharyngeal carcinoma II + - - + + + + +
Hodgkin's disease II + - - + + + + +
T-cell lymphoma II + - - + + + + +
EBV-transformed B cells III + + + + + + +
B-lymphoproliferation III + + + + + + +
in immunodeficiency
Gastric carcinoma + _ +
± a +
apositive in 3/7 (43%) cases.
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1995b), because the vast majority of Fp-initiated lytic
transcripts appeared not to contain the K exon (Schaefer et
al., 1995a and b) and, in addition, all tumour tissues
examined showed no evidence of lytic infection (see below).
Thus, the results indicated that Qp, not Cp or Wp, mediated
EBNA transcription in gastric carcinoma.
Analyses ofBZLFJ gene expression in EBV-positive gastric
carcinomas
Figure 4 shows the results of RT-PCR analysis demonstrat-
ing that none of the tumours showed evidence for expression
of BZLF1 mRNA. Similar negative results were also
obtained by immunofluorescent staining with the BZ.1
monoclonal antibody in frozen tissue sections (data not
shown). Since our RT-PCR system for detection of BZLF1
mRNA was sensitive enough to detect ten or fewer Akata
cells treated by surface IgG cross-linking (data not shown), in
which more than 80% of cells were positive for the BZLF1
antigen, EBV-positive gastric carcinoma was assumed to
harbour EBV in a non-permissive form.
Discussion
In the present study, we demonstrated that one of the three
hitherto identified EBNA promoters, Qp, was used in EBV-
cp
Wp W
wo
Cp
297 bp -,
Wp
235 bp *
positive gastric carcinomas, thus resulting in the selective
expression of EBNA1 mRNA, but not EBNA2 mRNA, as is
seen in BL and NPC (Liebowitz and Kieff, 1993). In
addition, neither LMP1 nor LMP2B mRNA was detectable
in any case examined. These findings were consistent with our
previous results showing by immunoblotting that EBV-
positive gastric carcinoma cells lacked EBNA2, -3A, -3B, -
3C, -LP and LMP1 proteins (Imai et al., 1994). All seven
EBV-positive tumours were also found to have BamHI-A
transcripts together with the EBNA1 message, presumably
corresponding to latency I of EBV infection typified by group
I BL cells (Kerr et al., 1992). However, LMP2A mRNA was
detected in three of seven cases tested, which may represent a
novel latency of EBV-related tumours distinct from
conventional latency I or II (Kerr et al., 1992). Interest-
ingly, this uniquely restricted pattern of latent gene
expression in a subgroup of EBV-positive gastric carcinomas
mostly resembled that observed in peripheral blood B
lymphocytes of healthy EBV-seropositive individuals (Qu
and Rowe, 1992; Tierney et al., 1994), which would be
advantageous for maintaining the life-long virus carrier state
under effective immunity.
It was shown by using an isogenic system of group I BL
cells that EBV indeed contributes to the malignant
phenotypes (Shimizu et al., 1994). Accordingly, since
EBNA1, the putative BamHI-A product and EBERs are
commonly expressed both in group I BL and in gastric
carcinoma cells, they may also be responsible, to some extent,
for the malignant features of gastric carcinoma. Recently a
possible role for EBNA1 in the EBV-induced oncogenic
process has been proposed in that its Gly-Ala repetitive
sequence inhibited the specific cytotoxic T-cell recognition of
immunodominant EBNA3B through a cis-acting mode
(Levitskaya et al., 1995). Several in vitro studies, however,
demonstrated that LMP1 potentially confers tumorigenicity
on non-lymphoid cells via transformation of established
rodent fibroblasts (Wang et al., 1985) and human keratino-
cytes (Fahraeus et al., 1990), inhibition of human epithelial
cell differentiation (Dawson et al., 1990), and induction of the
functional epidermal growth factor receptor (Miller et al.,
1995). Such important findings strongly support crucial roles
for LMP1 in the development ofundifferentiated NPC, where
the LMP1 positivity exceeds 80% of the cases at the
trancriptional level (Brooks et al., 1992; Chen et al., 1995).
The exact lack of LMP1 expression in EBV-positive gastric
carcinomas, irrespective of their histological phenotypes,
implies that LMP1 may not be necessary for the tumour, at
least to sustain its already established malignant state.
Rather, LMP1 might participate in an earlier stage of the
tumour development and be down-regulated thereafter.
Alternatively, the lack of LMP1 may reflect the result of
BZLF1
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Figure 3 RT-PCR analysis of promoter usage for EBNA gene
transcription in EBV-positive gastric carcinomas. Results are
shown by Et-Br staining (upper) and Southern hybridisation with
32P-labelled probes (lower). The structures of EBNA mRNA
transcribed from the three different promoters Cp, Wp and Qp
are shown by diagrams. Diagrammatic items and lanes represent
the same ones as in the legend of Figure 1. The predicted sizes of
each transcript are indicated at the left (bp).
Figure 4 RT-PCR analysis of immediate-early BZLF1 gene
expression in EBV-positive gastric carcinomas. Results are shown
by Et-Br staining (upper) and Southern hybridisation with a 32p_
labelled prope (lower). The splice structure of BZLF1 mRNA is
shown by a diagram on the top of an Et-Br-stained gel.
Diagrammatic items and lanes represent the same ones as in the
legend of Figure 1. The predicted size of BZLF1 mRNA is
indicated at the left (bp).
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clonal selection of LMP1-negative tumour cells by immuno-
logical pressure because EBV-specific cytotoxic T cells are
potentially directed against the viral latent proteins other
than EBNA1 (Khanna et al., 1992; Murray et al., 1992). In
fact, patients with EBV-positive gastric carcinoma have
normally retained virus-specific immune T-cell responses
(Imai et al., 1994) as is the case with BL (Rooney et al.,
1985), in contrast to NPC patients (Moss et al., 1983).
The EBV replication can be switched on in malignant or
non-malignant epithelial proliferative lesions in vivo; the
immediate-early BZLF1, the early and/or late antigens were
detected in NPC (Cochet et al., 1993), thymic carcinoma
(Patton et al., 1994) and AIDS-associated oral hairy
leucoplakia (OHL) (Greenspan et al., 1985). Similar viral
cycle events were also observed in vitro by experimental EBV
infection of cells of epithelial origin (Li et al., 1992; Sixbey
and Yao, 1992). There is a report of a patient with EBV-
positive undifferentiated gastric carcinoma, in which a very
small proportion of tumour cells expressed the BZLF1
protein, indicating that rare gastric carcinoma cells can
potentially enter the lytic cycle (Niedobitek et al., 1992). The
present study in contrast, showed that neither the BZLF1
mRNA nor protein was found in gastric carcinoma tissues,
results compatible with the absence of the early and viral
capsid antigens as previously reported (Imai et al., 1994). In
addition, although EBV latency can be disrupted as epithelial
cells differentiate, as shown by observations in OHL (Young
et al., 1991), none of the gastric carcinomas with various
differentiations showed any evidence of virus production.
LMP2A, detectably expressed in three of our seven cases, was
shown to block calcium mobilisation in B cells, thereby
suppressing EBV replication (Miller et al., 1993, 1994). It is
unknown whether the finding can be extended to epithelial
cells; however, at least in certain EBV-positive gastric
carcinomas, the absence of tumour cells entering the lytic
cycle may be associated with LMP2A expression. It was
inferred from our series of data that, unlike in NPC or OHL
cells, virus replication was uncommon or abortive in gastric
carcinoma, and that the vast majority of tumour cells carried
EBV in a tightly latent fashion.
The strict localisation of EBV genomes and viral gene
expression only in tumour cells and their monoclonality (Oda
et al., 1993; Imai et al., 1994) strongly suggest that EBV may
be indeed involved, not a passenger, in the development of
virus-positive gastric carcinoma, although several questions
remain to be resolved. Further studies are necessary to
understand more direct oncogenic activities of EBV on
normal gastric mucosal epithelia and a factor(s) enhancing
them.
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